Finance

Beta
Lists
600196:SHA
Shanghai Fosun Pharmaceutical (Group) Ord Shs A
CN¥23.25
+2.20%
(+0.50) 1D
May 29, 3:00:03 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600196...
Open
CN¥22.77
High
CN¥23.60
Low
CN¥22.77
Mkt. cap
55.94B
Avg. vol.
19.46M
Volume
26.17M
P/E ratio
17.71
52-wk high
CN¥33.10
52-wk low
CN¥22.76
EPS
CN¥1.31
Shares outstanding
2.01B
No. of employees
41K
Open
CN¥22.77
High
CN¥23.60
Low
CN¥22.77
Mkt. cap
55.94B
Avg. vol.
19.46M
Volume
26.17M
P/E ratio
17.71
52-wk high
CN¥33.10
52-wk low
CN¥22.76
EPS
CN¥1.31
Shares outstanding
2.01B
No. of employees
41K
News stories
From sources across the web
Profile
Shanghai Fosun Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company. It is mostly owned by Fosun International. As of 2018, the A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index. The company was ranked 1,840th in 2020 edition of the Forbes Global 2000, a list of top listed companies of the world. Wikipedia
About Shanghai Fosun Pharmaceutical (Group) Ord Shs A
CEOLiu Yi | Wen Deyong
Employees40.6K
Founded1994
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
10.09B
9.88B
12.27B
10.07B
Cost of goods sold
5.22B
5.08B
5.65B
5.07B
Cost of revenue
5.22B
5.08B
5.65B
5.07B
Research and development expenses
979.21M
1.01B
1.28B
896.79M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.14B
3.10B
4.44B
3.27B
Operating expense
4.19B
4.04B
5.92B
4.19B
Total operating expenses
9.41B
9.12B
11.57B
9.26B
Operating income
685.50M
758.38M
699.05M
813.78M
Other non operating income
-4.87M
-116.85M
107.33M
2.03M
EBT including unusual items
1.37B
1.12B
1.27B
1.36B
EBT excluding unusual items
1.16B
1.49B
1.10B
1.21B
Income tax expense
212.30M
162.98M
82.80M
277.92M
Effective tax rate
15.49%
14.57%
6.50%
20.47%
Other operating expenses
49.69M
-92.19M
117.57M
19.04M
Net income
937.21M
821.33M
847.27M
870.83M
Net profit margin
9.28%
8.31%
6.91%
8.64%
Earnings per share
-
-
-
-
Interest and investment income
925.83M
1.05B
732.13M
689.67M
Interest expense
-323.25M
-321.25M
-291.32M
-296.51M
Net interest expenses
602.58M
727.28M
440.80M
393.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.38B
1.39B
1.47B
1.59B
Gain or loss from assets sale
-2.12M
2.12M
-69.35M
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more